Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 54
- Registration Number
- NCT00215501
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-01-13
- Target Recruit Count
- 21
- Registration Number
- NCT00215995
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇵🇷Ponce School of Medicine, Ponce, Puerto Rico
🇵🇷University of Puetro Rico Cancer Center, San Juan, Puerto Rico
Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-09-22
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 40
- Registration Number
- NCT00222443
- Locations
- 🇺🇸
Oklahoma University Health Sciences Center-Jimmy Everest Center, Oklahoma City, Oklahoma, United States
Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Gabi Chiorean, MD
- Target Recruit Count
- 22
- Registration Number
- NCT00216086
- Locations
- 🇺🇸
AP&S Clinic, Terre Haute, Indiana, United States
🇺🇸Elkhart Clinic, Elkhart, Indiana, United States
🇺🇸Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States
Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2006-04-21
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 24
- Registration Number
- NCT00209638
Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2005-10-28
- Lead Sponsor
- University Hospital, Rouen
- Target Recruit Count
- 43
- Registration Number
- NCT00213486
- Locations
- 🇫🇷
CHU de Rouen, Rouen, France
Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2005-09-21
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 23
- Registration Number
- NCT00209625
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2006-02-02
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 40
- Registration Number
- NCT00209664
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-12-06
- Target Recruit Count
- 80
- Registration Number
- NCT00201747
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 198
- Registration Number
- NCT00193596
- Locations
- 🇺🇸
Tower Oncology, Beverly Hills, California, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Jackson Oncology Associates, Jackson, Mississippi, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.